尼可地尔对行择期经皮冠状动脉介入治疗的急性非ST段抬高心肌梗死患者心功能及运动耐量的影响

摘要

目的 探讨尼可地尔对择期经皮冠状动脉介入治疗(PCI)术后急性非ST段抬高心肌梗死(NSTEMI)患者心功能及运动耐量的影响.方法 80例NSTEMI患者随机分成对照组、尼可地尔组,每组40例,对两组患者心功能及运动耐量进行6个月随访观察和比较.主要观察指标包括:左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、6分钟步行距离(6MWD)、美国纽约心脏病协会分级(NYHA分级)以及主要心血管不良事件(MACE).结果 两组基线心功能指标比较差异均无统计学意义(P>0.05),随访6个月时,尼可地尔组LVEF较前升高、LVEDD明显缩小、NYHA分级较前改善(P0.05).After six months,LVEF was significantly increased,LVEDD decreased significantly,NYHA classification was significantly improved in nicorandil group (P < 0.05 ).In control group,LVEF and NYHA classification were significantly improved (P < 0.05 ),but LVEDD was significantly increased as compared with baseline (P < 0.05 ).Patients were followed up for six months. The LVEF, LVEDD, 6MWD and NYHA classification of two groups were statistically significant (P <0.05),and the occurrence of MACEs in nicorandil group was significantly lower than that in control group (10.0％ vs 26.7％,P <0.05).Conclusion Nicorandil can improve heart function,increase exercise capacity and reduce the incidence of MACE in patients with NSTEMI after elective PCI.